Filing Analysis
Coya Therapeutics, Inc. filed an 8-K to furnish a press release regarding its results of operations for the fiscal quarter ended June 30, 2026. The filing serves as a formal disclosure of quarterly financial performance.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Fiscal quarter ended June 30, 2026
- The company is an 'emerging growth company' as defined by the SEC.
- Information provided under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
This is an amendment to a previous 8-K filing regarding the appointment of Mark H. Pavao to the Board of Directors. The amendment specifically reports his appointment to the Audit Committee, effective August 6, 2026.
📋 Key Facts
- Amendment (8-K/A) to an original report filed on April 2, 2026.
- Mark H. Pavao was originally appointed to the Board of Directors effective April 1, 2026.
- As of August 6, 2026, Mr. Pavao has been appointed to the Audit Committee.
- The Audit Committee now consists of Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand, and Mark H. Pavao.
Coya Therapeutics, Inc. held its Annual Meeting of Stockholders on June 25, 2026. The meeting resulted in the election of two Class I directors and the ratification of Weaver and Tidwell, L.L.P. as the company's independent auditor for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual Meeting held on June 25, 2026.
- Secretary Wilbur Ross elected to Class I director (9,168,496 votes 'For').
- Dieter Weinand elected to Class I director (10,566,702 votes 'For').
- Ratification of Weaver and Tidwell, L.L.P. as independent registered public accounting firm for FY 2026 was approved.
- The company is classified as an emerging growth company.
Coya Therapeutics, Inc. has entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell up to $30 million of its common stock. The company will pay a 3.0% commission on gross proceeds for shares sold under this facility.
🚩 Red Flags
- Potential for significant shareholder dilution depending on the company's current market capitalization
- Indicates a continued reliance on equity markets to fund operations, typical for micro-cap biotech firms
📋 Key Facts
- Agreement date: May 12, 2026
- Counterparty: Leerink Partners LLC acting as sales agent
- Maximum offering amount: $30,000,000 in common stock
- Commission: 3.0% of aggregate gross proceeds
- Offering method: 'At-the-market' equity offerings as defined in Rule 415
- Registration: Conducted via shelf registration statement on Form S-3 (File No. 333-289511)
Coya Therapeutics reported its Q1 2026 financial results and announced that the U.S. FDA has granted Fast Track Designation to its drug candidate COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
📋 Key Facts
- On May 11, 2026, the FDA granted Fast Track Designation to COYA 302 for ALS treatment.
- The company disclosed financial results for the fiscal quarter ended March 31, 2026, via a press release on May 12, 2026.
- COYA 302 is the company's lead candidate for neurodegenerative diseases.
- The filing includes Item 2.02 (Results of Operations) and Item 8.01 (Other Events).
Coya Therapeutics announced the resignation of Dr. Howard Berman from his roles as Executive Chairman and Board member, effective April 1, 2026. The company simultaneously appointed Mark H. Pavao as an independent director to fill the vacancy and entered into a separation agreement with Dr. Berman.
📋 Key Facts
- Dr. Howard Berman resigned as Executive Chairman and from the Board effective April 1, 2026.
- Mark H. Pavao was appointed as a Class III independent director effective April 1, 2026, with a term expiring in 2028.
- Dr. Berman will receive a prorated 2026 annual bonus at 100% of target and COBRA premium coverage through March 31, 2027.
- Dr. Berman's unvested stock options will continue to vest for 12 months post-separation, with a two-year exercise window for all vested options.
- New director Mark H. Pavao was granted 10,000 stock options vesting on the one-year anniversary of the grant.
Coya Therapeutics, Inc. issued a press release on March 16, 2026, disclosing its financial results for the fiscal year ended December 31, 2025. The filing is a routine disclosure of operations and financial condition as required by Item 2.02.
📋 Key Facts
- Report date: March 16, 2026
- Fiscal year covered: Ended December 31, 2025
- Item 2.02: Results of Operations and Financial Condition disclosed
- Exhibit 99.1: Press release dated March 16, 2026, furnished with the filing
Coya Therapeutics entered into a Securities Purchase Agreement to issue 2,522,727 shares of common stock at $4.40 per share, raising approximately $11.1 million in gross proceeds. The offering is led by Dr. Reddy’s Labs ($10.0M) and Greenlight Capital ($1.1M).
🚩 Red Flags
- Private placement (unregistered offering) requires a subsequent registration statement within 45-75 days, which may lead to potential dilution for existing shareholders upon resale.
📋 Key Facts
- Total gross proceeds: approximately $11.1 million.
- Offering price: $4.40 per share.
- Number of shares to be issued: 2,522,727 common shares.
- Purchasers: Dr. Reddy’s Labs ($10.0M) and Greenlight Capital ($1.1M).
- Use of proceeds: Tech transfer for low dose IL-2 (LD IL-2), scaling up manufacturing, and supporting commercial readiness of COYA 302.
- Expected closing date: On or about January 30, 2026.
- The company expects the funds to extend cash runway into the second half of 2027.
Coya Therapeutics, Inc. issued a letter to stockholders providing an update on its financial position and clinical trial timeline. The company reports a cash balance of $46.8 million with a projected runway into H2 2027.
🚩 Red Flags
- Clinical trial dependency: The company's valuation and survival are heavily tied to the upcoming Q1 2027 topline data readout.
📋 Key Facts
- Cash balance as of December 31, 2025 (unaudited) was $46.8 million.
- Projected cash runway extends into the second half of 2027.
- Topline data readout from the ALSTARS Phase 2 trial is expected in Q1 2027.
Coya Therapeutics announced positive results from an investigator-initiated proof of concept study involving a low-dose IL-2 and CTLA4-Ig combination treatment for Frontotemporal Dementia (FTD). The 6-month study in 9 patients showed enhanced Treg function and stability in cognitive scores without serious adverse events.
🚩 Red Flags
- Small sample size (n=9) limits the statistical significance and generalizability of the results.
📋 Key Facts
- Study involved 9 patients with Frontotemporal Dementia (FTD) over a 22-week dosing/follow-up period.
- Primary endpoints focused on safety and feasibility; no serious adverse events were observed.
- Most common adverse event was mild erythema at the injection site (33.3%).
- Data showed significant increases in Treg suppressive function, Treg percentage, CD25 MFI, and FOXP3 MFI starting as early as 2 weeks post-dosing.
- Cognitive stability observed: MOCA scores moved from baseline 13.5 to 14 at week 22; CDR-FTLD scores moved from 4.8 to 5.5.
Coya Therapeutics, Inc. announced the receipt of a $4.2 million milestone payment from Dr. Reddy’s Laboratories Ltd. This payment was triggered by the successful dosing of the first patient in the ALSTARS clinical trial for COYA 302.
📋 Key Facts
- Received a $4.2 million milestone payment on December 16, 2025.
- Payment is part of a Development and License Agreement dated December 5, 2023, with Dr. Reddy’s Laboratories Ltd. and its affiliate.
- The milestone was triggered by the dosing of the first patient in the ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS).
- First patient dosing was previously announced on December 9, 2025.
Coya Therapeutics, Inc. filed an 8-K to furnish a press release regarding its results of operations for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- The filing pertains to the quarterly results of operations for the period ending September 30, 2025.
- The company is an emerging growth company.
- A press release was issued on November 12, 2025, as Exhibit 99.1.
Coya Therapeutics, Inc. entered into an underwriting agreement for a public offering of 4,181,818 shares of common stock at $5.50 per share. The offering is expected to raise approximately $23 million in gross proceeds.
🚩 Red Flags
- Dilutive offering of common stock for an emerging growth company.
- Issuance of warrants to financial advisor (100,000 shares at $5.50) which may cause further dilution.
📋 Key Facts
- Offering size: 4,181,818 total shares (includes 545,454 shares via underwriter option).
- Offering price: $5.50 per share.
- Estimated gross proceeds: Approximately $23.0 million.
- Underwriter: Lucid Capital Markets, LLC.
- Financial Advisor: Wilmington Capital Securities, LLC (receiving $200,000 fee and 100,000 warrants).
- Lock-up period: Directors and officers are subject to a lock-up expiring January 22, 2026.
- Expected closing date: On or about October 27, 2025.
Coya Therapeutics received a $4.2 million milestone payment from Dr. Reddy’s Laboratories Ltd. (DRL) following FDA acceptance of an IND for its Phase 2 study of COYA 302 in treating ALS. A second $4.2 million payment is triggered upon the dosing of the first patient in this study.
📋 Key Facts
- Received a $4.2 million milestone payment on August 29, 2025.
- Payment triggered by FDA acceptance of an IND for the Phase 2 Study of COYA 302 for ALS treatment.
- The study is described as a 'Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE)'.
- An additional $4.2 million milestone payment is due upon the dosing of the first patient in the Phase 2 Study.
- The underlying partnership is governed by a Development and License Agreement dated December 5, 2023.
Coya Therapeutics, Inc. filed an 8-K to furnish a press release regarding its results of operations for the fiscal quarter ended June 30, 2025. The filing serves as a mechanism to satisfy Regulation FD requirements by disclosing financial performance.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025.
- Filing date: August 12, 2025.
- The company is an emerging growth company.
- The filing includes a press release as Exhibit 99.1 regarding results of operations.
Coya Therapeutics announced that the FDA will miss its initial review goal date for the COYA 302 Phase 2 clinical study IND due to agency workload. The decision is now expected no later than August 29, 2025.
🚩 Red Flags
- Regulatory delay in clinical trial initiation (IND approval) due to FDA resource constraints.
📋 Key Facts
- The IND is for a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of COYA 302 for the treatment of ALS.
- The study includes a 24-week primary phase and a 24-week Open Label Extension (OLE).
- Initial FDA review goal date was July 30, 2025.
- FDA cited 'present workload and lack of resources' as the reason for the delay.
- New expected decision deadline: August 29, 2025.
Coya Therapeutics has re-submitted an Investigational New Drug (IND) application to the FDA, including additional non-clinical data requested by the agency. This submission is a prerequisite for initiating their planned Phase 2 clinical study of COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
🚩 Red Flags
- Regulatory delay: The company has been addressing an FDA request for additional data since at least July 2024, indicating a prolonged timeline for clinical progression.
📋 Key Facts
- Company re-submitted IND application on June 30, 2025.
- The submission includes additional non-clinical data requested by the FDA in July 2024.
- Target study: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study (with a 24-week Open Label Extension) for COYA 302.
- Indication: Amyotrophic Lateral Sclerosis (ALS).
- Clinical trial initiation is contingent upon FDA acceptance of the re-submitted IND.
Coya Therapeutics, Inc. held its Annual Meeting of Stockholders on June 26, 2025. The meeting resulted in the election of three Class III directors and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm.
📋 Key Facts
- Annual Meeting held on June 26, 2025.
- Election of Howard Berman, Ph.D., Arun Swaminathan, Ph.D., and Ann Lee, Ph.D., as Class III directors for three-year terms.
- Ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Voting results provided for both director elections and auditor ratification.
Coya Therapeutics, Inc. filed an 8-K to disclose its results of operations for the fiscal quarter ended March 31, 2025 via a press release.
📋 Key Facts
- The filing relates to the fiscal quarter ended March 31, 2025.
- Results were disclosed through a press release furnished under Item 2.02.
- The company is an emerging growth company.
Coya Therapeutics, Inc. filed an 8-K to disclose its results of operations for the fiscal year ended December 31, 2024 via a press release.
📋 Key Facts
- The filing relates to financial results for the fiscal year ending December 31, 2024.
- Information was disclosed via a press release furnished under Item 2.02.
- The company is an emerging growth company.
Coya Therapeutics, Inc. filed an 8-K to furnish a press release regarding its financial results for the fiscal quarter ended September 30, 2024.
📋 Key Facts
- The filing relates to results of operations and financial condition for the quarter ending September 30, 2024.
- Information was disclosed via a press release dated November 6, 2024 (Exhibit 99.1).
- The company is an emerging growth company.
Coya Therapeutics announced the immediate resignation of Dr. Hideki Garren from its Board of Directors, effective November 1, 2024.
📋 Key Facts
- Resignation date: November 1, 2024.
- Reason for departure: Compliance with a new employer's policy prohibiting board service at companies developing similar therapeutic compounds.
- The company explicitly stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Coya Therapeutics announced a leadership transition where Dr. Arun Swaminathan will succeed Dr. Howard Berman as CEO, effective November 1, 2024. Dr. Berman will transition from the CEO role to serve as Executive Chairman of the Board.
🚩 Red Flags
- Management turnover in the CEO position can sometimes signal internal strategic shifts or friction, though this appears to be a planned succession given the CBO is moving up.
📋 Key Facts
- Dr. Howard Berman is resigning as CEO effective October 31, 2024; he will remain on the Board as Executive Chairman.
- Dr. Arun Swaminathan (current CBO) appointed as new CEO effective November 1, 2024.
- Swaminathan's compensation includes a $525,000 base salary and a target annual bonus of up to 50% of base salary.
- Berman's compensation as Executive Chairman includes a $420,000 base salary and a target annual bonus of up to 50% of base salary.
- Both new employment agreements include 12-month severance provisions for termination without cause, contingent upon release of claims.
Coya Therapeutics announced Phase 2 clinical trial results for its LD IL-2 candidate in patients with mild to moderate Alzheimer’s Disease. The data was presented at the CTAD24 conference.
📋 Key Facts
- Announcement of placebo-controlled Phase 2 clinical trial results for LD IL-2.
- Target patient population: Mild to moderate Alzheimer’s Disease.
- Data presented at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid, Spain.
- Filing date: October 29, 2024.
Coya Therapeutics entered into a Securities Purchase Agreement on October 21, 2024, to issue 1,379,314 shares of common stock at $7.25 per share. The private placement is expected to raise approximately $10 million in gross proceeds to fund clinical and regulatory activities.
🚩 Red Flags
- Private placement involves unregistered securities that require a registration statement to be filed within 30-45 days.
📋 Key Facts
- Total offering size: 1,379,314 shares of common stock.
- Offering price: $7.25 per share.
- Expected gross proceeds: Approximately $10.0 million.
- Closing date: Expected on or about October 23, 2024.
- Placement agent fee: 7.0% of gross proceeds paid to BTIG, LLC and co-placement agents.
- Cash position as of Sept 30, 2024: Approximately $31.0 million (unaudited).
Coya Therapeutics announced a leadership transition where current CEO Dr. Howard Berman will resign effective October 31, 2024, to become Executive Chairman and consultant. He will be succeeded by the current Chief Business Officer, Arun Swaminathan, as CEO on November 1, 2024.
🚩 Red Flags
- CEO departure (though framed as a planned succession/transition to Chairman).
📋 Key Facts
- Dr. Howard Berman is resigning as CEO effective October 31, 2024; he will transition to Executive Chairman and a consultant for an expected 12-month term.
- Arun Swaminathan (current CBO) appointed to the Board as Class III director and will become CEO effective November 1, 2024.
- Dr. Swaminathan's current base salary is $425,000 with a potential annual bonus of 40% of base salary; compensation review pending for new role.
- The transition includes an anticipated consulting agreement between the Company and Dr. Berman.
Coya Therapeutics, Inc. issued an 8-K to disclose its results of operations for the fiscal quarter ended June 30, 2024 via a press release.
📋 Key Facts
- The filing relates to the fiscal quarter ended June 30, 2024.
- Information is furnished under Item 2.02 and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
- The company is an emerging growth company.
Coya Therapeutics announced that the FDA has requested additional non-clinical data regarding its Investigational New Drug (IND) application for COYA 302 in treating Amyotrophic Lateral Sclerosis (ALS). The FDA is expected to provide specific details on the required information within 30 days.
🚩 Red Flags
- Clinical development delay: The request for additional non-clinical data acts as a regulatory hurdle that will postpone the commencement of the Phase 2 study.
📋 Key Facts
- Company submitted an IND for a Phase 2 study of COYA 302 for ALS treatment on June 14, 2024.
- The proposed study is a 24-week randomized, double-blind, placebo-controlled trial with a 24-week open-label extension.
- FDA issued an email notification on July 12, 2024, requesting additional non-clinical data before the study can initiate.
- The FDA has committed to providing specific details regarding the required information within 30 days.
Coya Therapeutics entered into a First Amendment to its Development and License Agreement with Dr. Reddy's Laboratories on June 4, 2024. The amendment involves an upfront payment from Dr. Reddy's in exchange for royalty concessions.
🚩 Red Flags
- The company is sacrificing future royalty revenue ($6M) to secure immediate cash flow ($3.85M), suggesting a need for non-dilutive funding to advance clinical trials.
- The net economic value of the amendment appears negative or neutral depending on the timing and success of the drug, as the $6M in waived royalties exceeds the $3.85M upfront payment.
📋 Key Facts
- Dr. Reddy's will make a one-time payment of $3.85 million to Coya Therapeutics.
- The $3.85 million is earmarked specifically to fund the first phase 2 clinical trial of COYA 302 (IL-2 and CTLA-4 Ig co-pack kit) for amyotrophic lateral sclerosis in the US.
- In exchange, Dr. Reddy's will not be obligated to pay the first $6 million in royalty payments that were previously due under the original December 5, 2023 agreement.
Coya Therapeutics entered into a Securities Purchase Agreement with the Alzheimer’s Drug Discovery Foundation (ADDF) for a private placement of common stock. The transaction provides $5.0 million in gross proceeds to the company.
🚩 Red Flags
- Private placement involves unregistered securities (Section 4(a)(2) or Rule 506).
- Potential future dilution due to the requirement to register shares for resale by the purchaser.
📋 Key Facts
- Date of agreement: May 17, 2024
- Issuer: Coya Therapeutics, Inc. (COYA)
- Purchaser: Alzheimer’s Drug Discovery Foundation (ADDF)
- Number of shares issued: 603,136 common shares
- Price per share: $8.29
- Total gross proceeds: $5.0 million
- The company is required to file a registration statement for the resale of these shares within 30 days.
Coya Therapeutics, Inc. filed an 8-K to furnish a press release regarding its results of operations for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing is a disclosure of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The company is an emerging growth company.
Coya Therapeutics held its Annual Meeting of Stockholders on May 8, 2024. The meeting resulted in the election of two Class II directors and the approval of an amendment to increase the authorized share pool under the 2021 Equity Incentive Plan.
🚩 Red Flags
- Increase in authorized shares under equity incentive plan (potential dilution).
📋 Key Facts
- Annual Meeting held on May 8, 2024.
- Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 750,000 (totaling 2,571,070 shares).
- Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A. were elected as Class II directors for three-year terms.
- Stockholders ratified the appointment of Weaver and Tidwell, L.L.P. as independent registered public accounting firm for fiscal year 2024.
Coya Therapeutics, Inc. issued an 8-K to furnish a press release regarding its results of operations for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a disclosure of financial results for the fiscal year ending December 31, 2023.
- The report was filed on March 19, 2024.
- Information is provided under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Coya Therapeutics reported the receipt of a $7.5 million milestone payment from Dr. Reddy’s Laboratories under their existing development and license agreement. The company also outlined upcoming milestone payments related to its COYA 302 program for ALS.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Cash and cash equivalents as of Dec 31, 2023: $32.6 million (unaudited).
- Received $7.5 million from Dr. Reddy’s Laboratories Ltd. in January 2024.
- Pro forma cash position (including Jan payment) as of Dec 31, 2023: $40.1 million.
- Upcoming milestone: $4.2 million upon FDA acceptance of IND application for COYA 302 (ALS).
- Upcoming milestone: $4.2 million upon dosing the first patient in Phase 2 trial for COYA 302 (ALS) in the US.
- Management expects cash to be sufficient into 2026.